The greatest promise of a new crop of immuno-oncology treatments likely comes from using them in combination with one another, clinicians say. And Bristol-Myers Squibb, maker of two such drugs, is looking to couple its blockbuster treatments in a package deal, rolling toward FDA approval with a tandem therapy.
Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it’s already made a $50 million anchor investment in. …read more […]